Pfizer Inc. (0Q1N)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 30.03 |
|---|---|
| 52-week range | 21.62 – 30.42 |
| Return, 1 month / 3 months | +6.7% / +22.3% |
| Return, 1 year / 3 years | +30.5% / +17.0% |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 28.9% |
| Worst drawdown (1 year) | -22.6% |
| Average daily value traded | 3.16M USD |
| Dividend yield | 5.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pfizer is a pharmaceutical company that researches, develops and makes medicines and vaccines for patients around the world. Its products cover areas such as cancer care, immunology, heart and metabolic health, and infectious disease, and it supplies hospitals, clinics, pharmacies and health systems. The company is based in New York City and operates research, manufacturing and commercial sites across many countries, serving both healthcare professionals and governments that purchase vaccines and treatments.
On this site Pfizer Inc. appears as a stock on the London Exchange (UK), code 0Q1N, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pfizer Inc. (0Q1N) trades on the London Exchange in UK. It last closed at USD 30.03 on 23 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 226 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 30.5% and over the last three months it rose 22.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 84 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.8% | ||
| From 52-week high | -0.8% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 22.3% | ||
| 6-month return | 17.2% | ||
| 12-month return, skipping the last month | 22.3% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.6% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.16M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 83 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 5.7% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.8% |
|---|---|
| 1 month | +6.7% |
| 3 months | +22.3% |
| 6 months | +17.2% |
| 1 year | +30.5% |
| 3 years | +17.0% |
| 5 years | −8.6% |
Signals
| 50-day / 200-day average | 28.33 / 26.17 |
|---|---|
| Golden / death cross (60 days) | Golden, 40 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.66 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Jul 2026 | USD 0.4300 |
| 7 May 2026 | USD 0.4300 |
| 22 Jan 2026 | USD 0.4300 |
| 6 Nov 2025 | USD 0.4300 |
| 24 Jul 2025 | USD 0.4300 |
| 8 May 2025 | USD 0.4300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.